07.01.12
Nutraceutical: Omega 3s
Indication: Cardiovascular outcomes in people with diabetes
Source: N Engl J Med, Doi: 10.1056/NEJMoa1203859.
Research: In this double-blind study with a 2-by-2 factorial design, researchers randomly assigned 12,536 patients who were at high risk for cardiovascular events and had impaired fasting glucose, impaired glucose tolerance, or diabetes to receive a 1-gram capsule containing at least 900 mg (90% or more) of ethyl esters of omega 3 fatty acids or placebo daily, and to receive either insulin glargine or standard care. The primary outcome was death from cardiovascular causes.
Results: During a median follow up of 6.2 years, the incidence of the primary outcome was not significantly decreased among patients receiving omega 3 fatty acids, as compared with those receiving placebo (574 patients vs. 581 patients). The use of omega 3 fatty acids also had no significant effect on the rates of major vascular events, death from any cause or death from arrhythmia. Triglyceride levels were reduced by 14.5 mg per deciliter more among patients receiving omega 3 fatty acids than among those receiving placebo, without a significant effect on other lipids. Adverse effects were similar in the two groups. Daily supplementation with 1 gram of omega 3 fatty acids did not reduce the rate of cardiovascular events in patients at high risk for cardiovascular events.
Indication: Cardiovascular outcomes in people with diabetes
Source: N Engl J Med, Doi: 10.1056/NEJMoa1203859.
Research: In this double-blind study with a 2-by-2 factorial design, researchers randomly assigned 12,536 patients who were at high risk for cardiovascular events and had impaired fasting glucose, impaired glucose tolerance, or diabetes to receive a 1-gram capsule containing at least 900 mg (90% or more) of ethyl esters of omega 3 fatty acids or placebo daily, and to receive either insulin glargine or standard care. The primary outcome was death from cardiovascular causes.
Results: During a median follow up of 6.2 years, the incidence of the primary outcome was not significantly decreased among patients receiving omega 3 fatty acids, as compared with those receiving placebo (574 patients vs. 581 patients). The use of omega 3 fatty acids also had no significant effect on the rates of major vascular events, death from any cause or death from arrhythmia. Triglyceride levels were reduced by 14.5 mg per deciliter more among patients receiving omega 3 fatty acids than among those receiving placebo, without a significant effect on other lipids. Adverse effects were similar in the two groups. Daily supplementation with 1 gram of omega 3 fatty acids did not reduce the rate of cardiovascular events in patients at high risk for cardiovascular events.